Erel Joffe

24PUBLICATIONS
124CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Sep 30, 2026
A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignancies.

|Aug 31, 2026
Tumor CD19 Expression Determines Distinct Clinical Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

|Apr 29, 2026
Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.

|Jan 28, 2026
Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Erel Joffe, Anita Kumar, Joseph M Tuscano

|Jan 28, 2026
Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I Study.

Erel Joffe, Zachary Epstein-Peterson, Lorenzo Falchi

|Sep 14, 2023
Very low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.

Morgan E Freret, Kathryn R Tringale, Lillian Boe

Pageof 4

Frequent Collaborators

8 joint publications

Gilles Salles

6 joint publications

Maria Lia Palomba

6 joint publications

Andrew Zelenetz

5 joint publications

Lorenzo Falchi